SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
SeaStar Medical (NASDAQ: ICU) has achieved significant progress in its NEUTRALIZE-AKI pivotal clinical trial, reaching 125 patient enrollments, representing over 60% of the targeted 200 patients. The company has expanded its trial network to 16 clinical sites with the addition of Methodist Hospital Metropolitan in San Antonio, Texas.
The company remains on schedule for a third quarter 2025 interim analysis of the first 100 patients by the independent Data Safety Monitoring Review Board (DSMB). The trial includes prestigious institutions such as Cleveland Clinic, Mayo Clinic, and Stanford Medical Center, focusing on evaluating SCD therapy for adult patients with Acute Kidney Injury (AKI).
SeaStar Medical (NASDAQ: ICU) ha raggiunto importanti traguardi nel suo studio clinico cardine NEUTRALIZE-AKI, arrivando a 125 pazienti arruolati, pari a oltre il 60% dell'obiettivo di 200 pazienti. L'azienda ha ampliato la rete dello studio a 16 centri clinici con l'aggiunta del Methodist Hospital Metropolitan di San Antonio, Texas.
L'azienda mantiene la tabella di marcia per un'analisi intermedia nel terzo trimestre 2025 sui primi 100 pazienti, condotta dal comitato indipendente di revisione della sicurezza dei dati (DSMB). Lo studio coinvolge istituzioni prestigiose come la Cleveland Clinic, la Mayo Clinic e lo Stanford Medical Center, concentrandosi sulla valutazione della terapia SCD per pazienti adulti con lesione renale acuta (AKI).
SeaStar Medical (NASDAQ: ICU) ha logrado avances significativos en su ensayo clínico pivotal NEUTRALIZE-AKI, alcanzando 125 pacientes inscritos, lo que representa más del 60% de los 200 pacientes previstos. La compañía ha ampliado su red de ensayos a 16 centros clínicos con la incorporación del Methodist Hospital Metropolitan en San Antonio, Texas.
La empresa mantiene el cronograma para un análisis intermedio en el tercer trimestre de 2025 de los primeros 100 pacientes, realizado por la Junta Independiente de Supervisión de Seguridad de Datos (DSMB). El ensayo incluye instituciones prestigiosas como Cleveland Clinic, Mayo Clinic y Stanford Medical Center, enfocándose en evaluar la terapia SCD para pacientes adultos con lesión renal aguda (AKI).
SeaStar Medical (NASDAQ: ICU)는 NEUTRALIZE-AKI 주요 임상시험에서 중요한 진전을 이루어 125명의 환자 등록을 완료했으며, 이는 목표인 200명의 60% 이상에 해당합니다. 회사는 텍사스 샌안토니오에 위치한 Methodist Hospital Metropolitan을 추가하여 임상 시험 네트워크를 16개 임상 사이트로 확장했습니다.
회사는 독립 데이터 안전성 모니터링 심의위원회(DSMB)가 첫 100명의 환자에 대해 2025년 3분기 중간 분석을 실시하는 일정에 맞춰 진행 중입니다. 이 임상시험에는 Cleveland Clinic, Mayo Clinic, Stanford Medical Center와 같은 명망 있는 기관들이 참여하며, 급성 신손상(AKI) 성인 환자를 대상으로 SCD 치료법을 평가하는 데 중점을 두고 있습니다.
SeaStar Medical (NASDAQ : ICU) a réalisé des progrès significatifs dans son essai clinique pivot NEUTRALIZE-AKI, atteignant 125 patients enrôlés, soit plus de 60 % des 200 patients ciblés. La société a étendu son réseau d'essais à 16 sites cliniques avec l'ajout du Methodist Hospital Metropolitan à San Antonio, Texas.
L'entreprise reste dans les temps pour une analyse intermédiaire au troisième trimestre 2025 des 100 premiers patients par le comité indépendant de surveillance de la sécurité des données (DSMB). L'essai inclut des institutions prestigieuses telles que la Cleveland Clinic, la Mayo Clinic et le Stanford Medical Center, et se concentre sur l'évaluation de la thérapie SCD pour les patients adultes souffrant d'insuffisance rénale aiguë (IRA).
SeaStar Medical (NASDAQ: ICU) hat bedeutende Fortschritte in seiner entscheidenden NEUTRALIZE-AKI-Studie erzielt und 125 Patienteneinschreibungen erreicht, was über 60 % der angestrebten 200 Patienten entspricht. Das Unternehmen hat sein Studiennetzwerk auf 16 klinische Standorte erweitert, darunter das Methodist Hospital Metropolitan in San Antonio, Texas.
Das Unternehmen bleibt im Zeitplan für eine Zwischenanalyse im dritten Quartal 2025 der ersten 100 Patienten durch das unabhängige Data Safety Monitoring Board (DSMB). Die Studie umfasst renommierte Einrichtungen wie die Cleveland Clinic, die Mayo Clinic und das Stanford Medical Center und konzentriert sich auf die Bewertung der SCD-Therapie bei erwachsenen Patienten mit akutem Nierenversagen (AKI).
- Trial enrollment has reached 125 patients, achieving over 60% of target enrollment
- Expansion to 16 clinical trial sites with addition of Methodist Hospital Metropolitan
- On track for interim analysis in Q3 2025
- Participation of prestigious institutions including Cleveland Clinic, Mayo Clinic, and Stanford Medical Center
- None.
Insights
SeaStar Medical's pivotal AKI trial reaches 60% enrollment with interim analysis on track, showing steady clinical development progress.
SeaStar Medical's NEUTRALIZE-AKI pivotal trial has reached a significant enrollment milestone, with
The upcoming interim analysis by the independent Data Safety Monitoring Review Board (DSMB) in Q3 2025 represents a critical checkpoint. This analysis of the first 100 patients will evaluate both safety parameters and preliminary efficacy signals. The company's decision to disclose only top-line DSMB recommendations follows proper clinical trial conduct by preserving study integrity.
The trial's strategic design is notable - it's specifically powered to detect efficacy signals while maintaining rigorous safety monitoring. The impressive roster of participating institutions, including Cleveland Clinic, Mayo Clinic, and Stanford Medical Center, lends significant credibility to the study and indicates strong clinical interest in addressing the unmet needs in acute kidney injury requiring continuous renal replacement therapy (CRRT).
This milestone suggests SeaStar is maintaining expected enrollment rates for this pivotal trial of their Selective Cytophoretic Device (SCD) therapy. For a small commercial-stage company, consistent progress in a pivotal trial represents a crucial development that could potentially expand their therapeutic offerings in critical care nephrology.
Trial now over
Recent new site activation brings total clinical trial sites to 16
Interim analysis of first 100 patients remains on track for 3Q 2025
DENVER, Aug. 06, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached enrollment of 125 patients in the NEUTRALIZE-AKI pivotal clinical trial. Additionally, it has activated Methodist Hospital Metropolitan of San Antonio, Texas, as its 16th clinical trial site.
The company also reported that it remains on track to receive results from the per protocol prespecified interim analysis of the first 100 patients in the trial in the third quarter of 2025. The analysis is being conducted by the trial’s independent Data Safety Monitoring Review Board (DSMB). The company intends to disclose to its stakeholders only the top-line decision from the analysis by the DSMB to preserve the integrity to the ongoing trial.
“We are very pleased to reach this new enrollment milestone in the NEUTRALIZE-AKI pivotal trial,” stated Kevin Chung, MD, Chief Medical Officer of Sea Star Medical. “We are also thrilled to welcome Methodist Hospital Metropolitan as a key addition to our clinical trial sites. Its affiliate, Methodist Hospital, is one of our highest enrolling sites, and we believe their shared research teams and recruitment efforts should enable expedited recruitment and enrollment of patients in the NEUTRALIZE-AKI pivotal trial.”
Dr. Chung continued, “With respect to our upcoming interim analysis, the NEUTRALIZE-AKI pivotal trial is rigorously powered to detect a true efficacy signal, and confirming safety remains a top priority. This interim analysis seeks to validate the therapy’s safety profile and efficacy potential – critical factors in supporting a DSMB recommendation to proceed to full trial completion.”
A complete list of the NEUTRALIZE-AKI pivotal clinical trial sites can be viewed on ClinicalTrials.gov and includes notable institutions, such as Cleveland Clinic, Mayo Clinic, and Stanford Medical Center. The 16 clinical trial sites that are participating in the trial are clearly aware of the high unmet need of patients with AKI requiring CRRT. SeaStar Medical is grateful for their active participation in the trial.
About the NEUTRALIZE-AKI Pivotal Clinical Trial
NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) is a pivotal trial that is expected to enroll up to 200 adult patients with AKI requiring CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with SCD in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. The trial has enrolled 125 of 200 total anticipated patients. The per protocol interim analysis of the first 100 patients on the trial’s 90-day primary endpoint is being conducted by the trial’s independent DSMB. Secondary endpoints of the trial include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.
About the NEUTRALIZE-AKI Interim Analysis
The NEUTRALIZE-AKI pivotal clinical trial protocol specifies that an interim analysis will be conducted by the independent DSMB on the primary endpoint of the trial when approximately
About Acute Kidney Injury (AKI) and Hyperinflammation
AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as COVID-19, sepsis, severe trauma and surgery. AKI can cause hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face chronic kidney disease or end-stage renal disease requiring dialysis, among other complications. Hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.
About the FDA’s Breakthrough Device Designation
SeaStar Medical’s SCD therapy has been granted Breakthrough Device Designation for six indications, including the treatment of adult AKI requiring CRRT. FDA grants Breakthrough Device Designation when a device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. It must also represent one or more of the following: a) a breakthrough technology, b) a therapeutic treatment where no approved or cleared alternatives exist, c) offer significant advantages over existing approved or cleared alternative, and/or d) the device availability is in the best interest of patients. The Breakthrough Device Designation is designed to provide timely access to medical devices to speed up development, assessment, and review for FDA approval.
About the SeaStar Medical Selective Cytopheretic Device Therapy
The Selective Cytopheretic Device (SCD) therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy has broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing nearly a million patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future RRT, including dialysis, and prevent loss of life.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to anticipated patient benefits from our products; the expected regulatory approval process and timeline for our products; the anticipated timing of results from clinical trials; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
What is the current enrollment status of SeaStar Medical's NEUTRALIZE-AKI trial?
When will SeaStar Medical (ICU) release interim analysis results for the NEUTRALIZE-AKI trial?
Which major medical institutions are participating in SeaStar Medical's NEUTRALIZE-AKI trial?
What is the purpose of the NEUTRALIZE-AKI trial's interim analysis?
